Tandem Diabetes Care reported its first quarter 2025 financial results with GAAP earnings per share (EPS) of negative $1.97 and adjusted EPS of negative $0.67, missing the adjusted EPS estimate of negative $0.61. The company posted sales of $234.42 million, surpassing the estimated $220.20 million. DexCom also released its Q1 2025 results, reporting revenue of $1.04 billion, beating the $1.02 billion estimate, though its adjusted EPS of $0.32 slightly missed the $0.33 forecast. DexCom's GAAP EPS was $0.27, reflecting a 12% year-over-year revenue increase. The company highlighted expanded coverage in the U.S., with two of the three largest pharmacy benefit managers now supporting DexCom continuous glucose monitoring (CGM) systems. CareDx and Glaukos also announced their first quarter 2025 financial results, though specific figures were not provided. Adaptive Biotechnologies reported its Q1 2025 results as well, without detailed financial data disclosed.